What is Abionic?
Founded in 2010, Abionic is a Swiss MedTech company renowned for its pioneering work in rapid diagnostic solutions. The company's flagship abioSCOPE platform offers lab-quality results from a single drop of blood within minutes, directly at the point-of-care. This technology is crucial for enabling timely clinical decisions, particularly in emergency and intensive care settings for conditions such as sepsis. Abionic's commitment to enhancing diagnostic capabilities positions it as a key player aiming to improve patient outcomes globally.
How much funding has Abionic raised?
Abionic has raised a total of $7.7M across 2 funding rounds:
Series A
$3.7M
Series B
$4M
Series A (2012): $3.7M, investors not publicly disclosed
Series B (2014): $4M led by Drexel Morgan & Co and BlueOcean Ventures SA
Key Investors in Abionic
Drexel Morgan & Co
Drexel Morgan & Co is an investment banking firm based in Radnor, Pennsylvania, likely focusing on providing capital and advisory services to companies within the technology and healthcare sectors.
BlueOcean Ventures SA
BlueOcean Ventures SA is an investment firm specializing in early-stage medical device and life science companies, aiming to support innovative ventures through strategic guidance and financial backing in untapped markets.
What's next for Abionic?
The recent major strategic investment signifies a pivotal moment for Abionic, likely enabling the company to accelerate its product development, expand its market reach, and further solidify its position in the global diagnostic solutions sector. This capital infusion is expected to fuel innovation and operational scaling, reinforcing Abionic's trajectory towards becoming a leader in point-of-care diagnostics.
See full Abionic company page
